Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426550 | 0.89 | TGFBR1 (0.40) | TGFBR1ACVR1BACVRL1CYP3A4LATS1 | |
| SCHEMBL12425323 | 0.89 | TGFBR1 (0.46) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL2298429 | 0.83 | TRPV1 (0.52) | TRPV1MAPK3MPLTGFBR1CYP3A4 | |
| SCHEMBL2301070 | 0.83 | ALDH1A1 (0.41) | TRPV1MAPK3MPL | |
| SCHEMBL12424755 | 0.82 | KDM4E (0.41) | TRPV1MAPK3KDM4ETGFBR1ACVR1B | |
| SCHEMBL2300323 | 0.81 | MPL (0.49) | TRPV1MAPK3MPLABCG2 | |
| SCHEMBL12424763 | 0.80 | TRPV1 (0.45) | TRPV1MAPK3KDM4EMPLABCG2 | |
| SCHEMBL12425347 | 0.78 | TRPV1 (0.42) | TRPV1MAPK3KDM4EMPLABCG2 | |
| SCHEMBL12441314 | 0.76 | MPL (0.44) | TRPV1KDM4ETRPV3MPLSUCNR1 | |
| SCHEMBL12426556 | 0.75 | TGFBR1 (0.47) | TGFBR1CYP3A4ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | TRPV1 4168/4885MAPK3 1961/4885KDM4E 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.